Compare Adaptive Biotechnologies Corp (ADPT) vs Funko Inc (FNKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Funko Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while Funko Inc trades at $6.23 (market cap $332.33M). The key difference: Adaptive Biotechnologies Corp is far larger — about 12.2× Funko Inc's market cap. Which is the better fit depends on your goals.
| ADPT | FNKO | |
|---|---|---|
Market Cap | $4.04B | $332.33M |
Sector | Health | Consumer Staples |
52-Week High | $25.45 | $6.35 |
52-Week Low | $12.30 | $2.65 |
Enterprise Value | $4.10B | $552.98M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
FNKO trades at $5.92, down 4.36% today, but maintains a bullish technical outlook with strong moving average signals. The company reported improved Q2 2026 results with 7% revenue growth to $207.7M and raised EBITDA guidance. Despite negative net margins, recent earnings beats and a low P/S ratio of 0.35 suggest undervaluation. Analyst sentiment is mixed with 43% buy ratings but no sell recommendations.
The outlook remains cautiously optimistic as Funko's turnaround strategy shows traction, though profitability challenges and negative cash flow from operations pose risks. The stock offers potential upside if management can sustain recent operational improvements and return to consistent profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →
